胰十二指肠切除术后常规鼻胃管减压与不减压的随机对照IPOD试验
IPOD为法国单中心开放标签随机对照试验,111例胰十二指肠切除患者1:1分入常规鼻胃管减压组或不减压组。主要终点Clavien-Dindo≥II级并发症发生率两组相似(RR 0.99,95%CI 0.66-1.47,P>.99),提示术后避免常规鼻胃管减压是安全的。
要点
- 胰十二指肠切除术后不常规留置鼻胃管减压未增加≥II级并发症。
- 肺部并发症与胃排空延迟发生率两组无显著差异。
- 不减压组住院时间中位数与减压组无显著差异。
核心结论
- 胰十二指肠切除术后常规鼻胃管减压与不减压的Clavien-Dindo≥II级并发症发生率无显著差异,避免常规减压对该适应证是安全的。
研究设计与样本
- IPOD为开放标签、前瞻性、单中心随机对照试验,在法国高容量胰腺外科大学医院开展。
- 共111例18至75岁需行胰十二指肠切除的良性或恶性疾病患者随机1:1分入常规鼻胃管减压组(n=59)或不减压组(n=52)。
- 不减压组术后立即拔除鼻胃管,减压组术后3至5天拔除,随访至术后90天。
主要发现
- 主要终点≥II级并发症发生率两组相似(风险比0.99,95%CI 0.66-1.47,P>.99)。
- 肺部并发症发生率两组无显著差异(风险比0.59,95%CI 0.18-1.95,P=.44)。
- 胃排空延迟发生率两组无显著差异(风险比1.07,95%CI 0.52-2.21,P>.99)。
- 不减压组住院时间中位数10.0天(四分位距9.0-16.3),减压组12.0天(10.0-16.0),差异无统计学意义(P=.14)。
临床怎么用
- 胰十二指肠切除术后可考虑不常规放置或术后立即拔除鼻胃管减压,不增加≥II级并发症风险。
局限性
- 单中心研究,样本量111例,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although standardization of pancreaticoduodenectomy (PD) has improved postoperative outcomes, morbidity remains high. Fast-track surgery programs appear to improve morbidity, and avoiding nasogastric tube decompression (NGTD), already outdated in most major abdominal surgery, is strongly suggested after PD by fast-track surgery programs but lacks high-level evidence, especially regarding safety. OBJECTIVE: To assess in a randomized clinical trial whether the absence of systematic NGTD after PD reduces postoperative complications. DESIGN, SETTING, AND PARTICIPANTS: The IPOD study (Impact of the Absence of Nasogastric Decompression After Pancreaticoduodenectomy) was an open-label, prospective, single-center, randomized clinical trial conducted at a high-volume pancreatic surgery university hospital in France. In total, 155 patients who were 18 to 75 years of age and required PD for benign or malignant disease were screened for study eligibility. Key exclusion criteria were previous gastric or esophageal surgery and severe comorbidities. Patients were randomly assigned (1:1) to systematic NGTD or to no nasogastric decompression and were followed up until 90 days after surgery. INTERVENTIONS: For patients without NGTD, the NGT was removed immediately after surgery, whereas for patients with NGTD, the NGT was removed 3 to 5 days after surgery. MAIN OUTCOMES AND MEASURES: The primary end point was the occurrence of postoperative complications grade II or higher using the Clavien-Dindo classification. The primary end point and safety were evaluated in the intent-to-treat population. RESULTS: From January 2016 to August 2018, 125 screened patients were considered eligible for the study, and 111 were randomized to no NGTD (n = 52) or to NGTD (n = 59). No patient was lost to follow-up. The 2 groups had similar patient demographic and clinical characteristics at baseline. The median (interquartile range) age was 63.0 (57.0-66.5) years in the group with NGTD (38 [64.4%] were males) and 64.0 (58.0-68.0) years in the group without NGTD (31 [59.6%] were males). The postoperative complication rates grade II or higher were similar between the 2 groups (risk ratio, 0.99; 95% CI, 0.66-1.47; P > .99). Pulmonary complication rates (risk ratio, 0.59; 95% CI, 0.18-1.95; P = .44) and delayed gastric emptying rates (risk ratio, 1.07; 95% CI, 0.52-2.21; P > .99) were not significantly different between the groups. Median (interquartile) length of hospital stay for patients without NGTD was not significantly different compared with those with NGTD (10.0 [9.0-16.3] vs 12.0 [10.0-16.0] days; P = .14). CONCLUSIONS AND RELEVANCE: The present study found no significant difference in postoperative complication occurrence of Clavien-Dindo classification grade II or higher between systematic NGTD and no NGTD after PD, suggesting that avoiding systematic nasogastric decompression is safe for this indication. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02594956.
引用
- Bergeat D, Merdrignac A, Robin F, et al. Nasogastric Decompression vs No Decompression After Pancreaticoduodenectomy: The Randomized Clinical IPOD Trial. JAMA Surg. 2020. PMID: 32667635. doi:10.1001/jamasurg.2020.2291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。